Literature DB >> 17314219

Toxin profiles and resistances to macrolides and newer fluoroquinolones as epidemicity determinants of clinical isolates of Clostridium difficile from Warsaw, Poland.

Hanna Pituch1, Willem van Leeuwen, Kees Maquelin, Dorota Wultańska, Piotr Obuch-Woszczatyński, Grazyna Nurzyńska, Haru Kato, Martin Reijans, Felicja Meisel-Mikołajczyk, Mirosław Łuczak, Alex van Belkum.   

Abstract

Amplified fragment length polymorphism genotypes, antibiotic resistance profiles, and toxin profiles of Clostridium difficile strains from Warsaw were determined. The isolates segregate in six major genotypes, coinciding with toxin profiles. Most of the toxin A-negative toxin B-positive toxin CDT-negative strains possess ermB, and several strains were resistant to fluoroquinolones. Resistograms and toxin types of C. difficile strains are epidemicity determinants.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17314219      PMCID： PMC1865912          DOI： 10.1128/JCM.00306-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  20 in total

1.  Comparative sequence analysis of the Clostridium difficile toxins A and B.

Authors:  C von Eichel-Streiber; R Laufenberg-Feldmann; S Sartingen; J Schulze; M Sauerborn
Journal:  Mol Gen Genet       Date:  1992-05

2.  High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.

Authors:  Denise Drudy; Teresa Quinn; Rebecca O'Mahony; Lorraine Kyne; Peadar O'Gaora; Séamus Fanning
Journal:  J Antimicrob Chemother       Date:  2006-10-03       Impact factor: 5.790

3.  Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile.

Authors:  S Stubbs; M Rupnik; M Gibert; J Brazier; B Duerden; M Popoff
Journal:  FEMS Microbiol Lett       Date:  2000-05-15       Impact factor: 2.742

4.  Definition of the single integration site of the pathogenicity locus in Clostridium difficile.

Authors:  V Braun; T Hundsberger; P Leukel; M Sauerborn; C von Eichel-Streiber
Journal:  Gene       Date:  1996-11-28       Impact factor: 3.688

5.  Prevalence and association of macrolide-lincosamide-streptogramin B (MLS(B)) resistance with resistance to moxifloxacin in Clostridium difficile.

Authors:  Grit Ackermann; Angelika Degner; Stuart H Cohen; Joseph Silva; Arne C Rodloff
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

6.  Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile.

Authors:  G Ackermann; Y J Tang-Feldman; R Schaumann; J P Henderson; A C Rodloff; J Silva; S H Cohen
Journal:  Clin Microbiol Infect       Date:  2003-06       Impact factor: 8.067

Review 7.  Nosocomial diarrhoea due to Clostridium difficile.

Authors:  Thomas V Riley
Journal:  Curr Opin Infect Dis       Date:  2004-08       Impact factor: 4.915

8.  Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping.

Authors:  Renate J van den Berg; Eric C J Claas; Duddy H Oyib; Corné H W Klaassen; Lenie Dijkshoorn; Jon S Brazier; Ed J Kuijper
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

9.  Multilocus sequence typing analysis of human and animal Clostridium difficile isolates of various toxigenic types.

Authors:  Ludovic Lemee; Anne Dhalluin; Martine Pestel-Caron; Jean-François Lemeland; Jean-Louis Pons
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Recent emergence of an epidemic clindamycin-resistant clone of Clostridium difficile among Polish patients with C. difficile-associated diarrhea.

Authors:  Hanna Pituch; Alex Van Belkum; Nicole Van Den Braak; Piotr Obuch-Woszczatynski; Henri Verbrugh; Felicja Meisel-Mikołajczyk; Mirosław uczak
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948
View more
  3 in total

1.  Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.

Authors:  Chun-Hsing Liao; Wen-Chien Ko; Jang-Jih Lu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

2.  tcdA As a diagnostic target in a loop-mediated amplification assay for detecting toxigenic Clostridium difficile.

Authors:  Brianne Couturier; Robert Schlaberg; Chris Konzak; Jeff Nicholes; Christian Law; Rosemary C She
Journal:  J Clin Lab Anal       Date:  2013-05       Impact factor: 2.352

3.  Clinical risk factors for severe Clostridium difficile-associated disease.

Authors:  Timothy J Henrich; Douglas Krakower; Asaf Bitton; Deborah S Yokoe
Journal:  Emerg Infect Dis       Date:  2009-03       Impact factor: 6.883
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.